MX2019015237A - Combinaciones que comprenden brexpiprazol o una sal del mismo y un segundo farmaco para el uso en el tratamiento de un trastorno del sistema nervioso central. - Google Patents
Combinaciones que comprenden brexpiprazol o una sal del mismo y un segundo farmaco para el uso en el tratamiento de un trastorno del sistema nervioso central.Info
- Publication number
- MX2019015237A MX2019015237A MX2019015237A MX2019015237A MX2019015237A MX 2019015237 A MX2019015237 A MX 2019015237A MX 2019015237 A MX2019015237 A MX 2019015237A MX 2019015237 A MX2019015237 A MX 2019015237A MX 2019015237 A MX2019015237 A MX 2019015237A
- Authority
- MX
- Mexico
- Prior art keywords
- drug
- treatment
- reuptake inhibitor
- brexpiprazole
- salt
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 6
- 229940079593 drug Drugs 0.000 title abstract 4
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 2
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 229960001210 brexpiprazole Drugs 0.000 title 1
- 208000015114 central nervous system disease Diseases 0.000 title 1
- 229940126570 serotonin reuptake inhibitor Drugs 0.000 abstract 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 abstract 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 abstract 1
- 230000000561 anti-psychotic effect Effects 0.000 abstract 1
- 229940125713 antianxiety drug Drugs 0.000 abstract 1
- 239000000164 antipsychotic agent Substances 0.000 abstract 1
- 239000003693 atypical antipsychotic agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000004050 mood stabilizer Substances 0.000 abstract 1
- 229940127237 mood stabilizer Drugs 0.000 abstract 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 abstract 1
- 230000002474 noradrenergic effect Effects 0.000 abstract 1
- 229960002748 norepinephrine Drugs 0.000 abstract 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 abstract 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 abstract 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 229940127228 tetracyclic antidepressant Drugs 0.000 abstract 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
Abstract
La presente invención proporciona un medicamento que tiene un mayor espectro de tratamiento, causando menores efectos colaterales y que es superior en tolerabilidad y seguridad, en comparación con agentes antipsicóticos típicos y agentes antipsicóticos atípicos conocidos. La presente invención se refiere a un medicamento que contiene (I) un compuesto que es 7-[4-(4-benzo[b]tiofen-4-il-piperazin-1-il)butoxi]-1H-quinolin-2- ona o una de sus sales y (II) al menos un fármaco seleccionado del grupo que consiste en un estabilizador del estado de ánimo, un inhibidor de la reabsorción de serotonina, un inhibidor de la reabsorción de norepinefrina, un inhibidor de la reabsorción de serotonina y norepinefrina, un antidepresivo noradrenérgico y serotonérgico específico, un fármaco antiansiedad, un antidepresivo tricíclico, un antidepresivo tetracíclico, un fármaco antipsicótico y un fármaco anti-ADHD, en combinación.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161471911P | 2011-04-05 | 2011-04-05 | |
| US201161580540P | 2011-12-27 | 2011-12-27 | |
| PCT/JP2012/059825 WO2012137971A1 (en) | 2011-04-05 | 2012-04-04 | Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019015237A true MX2019015237A (es) | 2020-02-13 |
| MX390286B MX390286B (es) | 2025-03-20 |
Family
ID=46045045
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013010796A MX370670B (es) | 2011-04-05 | 2012-04-04 | Combinaciones que comprenden brexipiprazol o una sal del mismo y un segundo farmaco para el uso en el tratamiento de un trastorno del sistema nervioso central. |
| MX2019015237A MX390286B (es) | 2011-04-05 | 2012-04-04 | Combinaciones que comprenden brexpiprazol o una sal del mismo y un segundo farmaco para el uso en el tratamiento de un trastorno del sistema nervioso central. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013010796A MX370670B (es) | 2011-04-05 | 2012-04-04 | Combinaciones que comprenden brexipiprazol o una sal del mismo y un segundo farmaco para el uso en el tratamiento de un trastorno del sistema nervioso central. |
Country Status (33)
| Country | Link |
|---|---|
| US (7) | US20140120185A1 (es) |
| EP (5) | EP4023223A1 (es) |
| JP (2) | JP5992924B2 (es) |
| KR (1) | KR101890450B1 (es) |
| CN (2) | CN108042808B (es) |
| AR (1) | AR085840A1 (es) |
| AU (1) | AU2012240864B2 (es) |
| BR (1) | BR112013025420B1 (es) |
| CA (1) | CA2832157C (es) |
| CO (1) | CO6801769A2 (es) |
| CY (1) | CY1120567T1 (es) |
| DK (1) | DK2694043T3 (es) |
| EA (1) | EA035837B1 (es) |
| ES (1) | ES2654851T3 (es) |
| HK (1) | HK1246159A1 (es) |
| HR (1) | HRP20180098T1 (es) |
| HU (1) | HUE035542T2 (es) |
| IL (1) | IL228669B (es) |
| JO (2) | JOP20120083B1 (es) |
| LT (1) | LT2694043T (es) |
| MX (2) | MX370670B (es) |
| MY (1) | MY166936A (es) |
| NZ (1) | NZ615591A (es) |
| PH (3) | PH12013501908A1 (es) |
| PL (1) | PL2694043T3 (es) |
| PT (1) | PT2694043T (es) |
| RS (1) | RS56802B1 (es) |
| SG (2) | SG10201602326RA (es) |
| SI (1) | SI2694043T1 (es) |
| SM (1) | SMT201800033T1 (es) |
| TW (1) | TWI636784B (es) |
| WO (1) | WO2012137971A1 (es) |
| ZA (1) | ZA201306981B (es) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3753B1 (ar) * | 2011-10-14 | 2021-01-31 | Otsuka Pharma Co Ltd | قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه |
| TWI679977B (zh) * | 2011-10-19 | 2019-12-21 | 大塚製藥股份有限公司 | 口服溶液 |
| TW201332572A (zh) * | 2011-12-28 | 2013-08-16 | Otsuka Pharma Co Ltd | 具有經取代的β－環糊精之藥物製劑 |
| JOP20200109A1 (ar) | 2012-04-23 | 2017-06-16 | Otsuka Pharma Co Ltd | مستحضر قابل للحقن |
| JOP20210047A1 (ar) * | 2012-10-25 | 2017-06-16 | Otsuka Pharma Co Ltd | عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه |
| EP2968237A4 (en) * | 2013-03-15 | 2016-08-31 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION |
| SG10201809280PA (en) | 2014-04-22 | 2018-11-29 | Otsuka Pharma Co Ltd | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders |
| US20170196846A1 (en) * | 2014-06-06 | 2017-07-13 | Rhodes Pharmaceuticals, L.P. | Methods for treating attention deficit hyperactivity disorder with methylphenidate |
| CA3018328A1 (en) | 2014-10-31 | 2016-04-30 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| AU2017240259A1 (en) | 2016-04-01 | 2018-10-18 | Upmc | Regulatory device and associated method |
| EP3500249A1 (en) | 2016-08-16 | 2019-06-26 | Hexal Aktiengesellschaft | Pharmaceutical compositions of a benzothiophene compound |
| EP3500247B1 (en) | 2016-08-16 | 2020-05-27 | H e x a l Aktiengesellschaft | Immediate release tablet of a benzothiophene compound |
| DK3532064T3 (da) * | 2016-10-28 | 2020-08-24 | H Lundbeck As | Kombinationsbehandlinger omfattende imidazopyrazinoner til behandlingen af psykiatriske og/eller kognitive lidelser |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| EP3501506B1 (en) * | 2017-12-19 | 2019-10-09 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Pharmaceutical tablet composition comprising brexpiprazole |
| JP2019183095A (ja) * | 2018-08-16 | 2019-10-24 | 株式会社Ｄｎｐファインケミカル | 接着性粉体、接着性錠剤の製造方法、接着性錠剤、並びに該接着性粉体及び錠剤を用いた部材又は部品の製造方法 |
| JP6831354B2 (ja) * | 2018-08-16 | 2021-02-17 | 株式会社Ｄｎｐファインケミカル | 接着性組成物からなる錠剤、その製造方法、及び該錠剤を用いた部材又は部品の製造方法 |
| WO2020070267A1 (en) * | 2018-10-04 | 2020-04-09 | École Polytechnique Fédérale De Lausanne (Epfl) | Cross-linkable polymer, hydrogel, and method of preparation thereof |
| KR20210102211A (ko) * | 2018-10-24 | 2021-08-19 | 이펙터 테라퓨틱스, 인크. | Mnk 억제제의 결정질 형태 |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
| AU2020258086A1 (en) | 2019-04-17 | 2021-11-11 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| WO2021029020A1 (ja) * | 2019-08-13 | 2021-02-18 | 大塚製薬株式会社 | 経口医薬組成物 |
| US11229644B1 (en) * | 2020-12-31 | 2022-01-25 | Lake O'hara Llc | Methods of treating psychiatric disorders in obese patients with brexpiprazole |
| CN113322299A (zh) * | 2021-05-28 | 2021-08-31 | 南昌大学 | 一种抑郁症和药物成瘾疾病的药物靶点识别方法 |
| CN116407539B (zh) * | 2021-12-30 | 2025-01-10 | 上海现代药物制剂工程研究中心有限公司 | 依匹哌唑甲基脂肪酸酯的用途 |
| US20240009181A1 (en) * | 2022-07-08 | 2024-01-11 | Jason Eric Schiffman | Method for the treatment and prophylaxis of substance-related and/or addictive disorders including substance/medication-induced depressive disorders, bipolar and related disorders, and anxiety disorders and compositions useful for the same |
| FR3142667A1 (fr) * | 2022-12-01 | 2024-06-07 | Capsum | Composition solide non pulvérulente comprenant au moins 8% en poids d’agent(s) désintégrant |
| US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
| TR2023018022A1 (tr) * | 2023-12-22 | 2025-07-21 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Brekspi̇prazol i̇çeren bi̇r tablet |
| TR2023018024A1 (tr) * | 2023-12-22 | 2025-07-21 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Brekspi̇prazol i̇çeren tabletler |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5178878A (en) | 1989-10-02 | 1993-01-12 | Cima Labs, Inc. | Effervescent dosage form with microparticles |
| IL121076A (en) * | 1996-06-19 | 2000-10-31 | Akzo Nobel Nv | Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors |
| IL123716A (en) * | 1997-03-27 | 2001-03-19 | Akzo Nobel Nv | Therapeutic combinations of mirtazapine and an antipsychotic agent |
| US6024981A (en) | 1997-04-16 | 2000-02-15 | Cima Labs Inc. | Rapidly dissolving robust dosage form |
| CA2451914A1 (en) * | 2001-08-08 | 2003-02-20 | John-Michael Sauer | Combination therapy for the treatment of neurological disorders |
| RU2356554C2 (ru) * | 2002-12-27 | 2009-05-27 | Оцука Фармасьютикал Ко., Лтд. | Производные карбостирила и ингибиторы обратного захвата серотонина для лечения эмоциональных расстройств |
| JP2008504295A (ja) * | 2004-06-25 | 2008-02-14 | ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム | 注意欠陥多動性障害及び高フェニルアラニン血症の治療のための方法及び組成物 |
| TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
| JP4315393B2 (ja) * | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
| JP4540700B2 (ja) * | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
| JP2010508279A (ja) * | 2006-10-27 | 2010-03-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 破壊的行動障害の処置法 |
| JP2008189616A (ja) * | 2007-02-07 | 2008-08-21 | Mitsubishi Tanabe Pharma Corp | 注意欠陥多動性障害の治療薬 |
| JP2011136906A (ja) * | 2008-04-18 | 2011-07-14 | Otsuka Pharmaceut Co Ltd | 複素環化合物 |
-
2012
- 2012-04-03 JO JOP/2012/0083A patent/JOP20120083B1/ar active
- 2012-04-03 AR ARP120101135A patent/AR085840A1/es unknown
- 2012-04-03 TW TW101111875A patent/TWI636784B/zh active
- 2012-04-04 EA EA201391450A patent/EA035837B1/ru not_active IP Right Cessation
- 2012-04-04 SG SG10201602326RA patent/SG10201602326RA/en unknown
- 2012-04-04 MX MX2013010796A patent/MX370670B/es active IP Right Grant
- 2012-04-04 PT PT127194603T patent/PT2694043T/pt unknown
- 2012-04-04 US US14/009,436 patent/US20140120185A1/en not_active Abandoned
- 2012-04-04 SM SM20180033T patent/SMT201800033T1/it unknown
- 2012-04-04 EP EP22155365.4A patent/EP4023223A1/en not_active Withdrawn
- 2012-04-04 PH PH1/2013/501908A patent/PH12013501908A1/en unknown
- 2012-04-04 EP EP19205895.6A patent/EP3626243A1/en not_active Withdrawn
- 2012-04-04 MX MX2019015237A patent/MX390286B/es unknown
- 2012-04-04 AU AU2012240864A patent/AU2012240864B2/en active Active
- 2012-04-04 EP EP25173601.3A patent/EP4570250A3/en active Pending
- 2012-04-04 HR HRP20180098TT patent/HRP20180098T1/hr unknown
- 2012-04-04 LT LTEP12719460.3T patent/LT2694043T/lt unknown
- 2012-04-04 BR BR112013025420-3A patent/BR112013025420B1/pt active IP Right Grant
- 2012-04-04 RS RS20180064A patent/RS56802B1/sr unknown
- 2012-04-04 KR KR1020137029250A patent/KR101890450B1/ko active Active
- 2012-04-04 WO PCT/JP2012/059825 patent/WO2012137971A1/en not_active Ceased
- 2012-04-04 EP EP12719460.3A patent/EP2694043B1/en not_active Revoked
- 2012-04-04 HU HUE12719460A patent/HUE035542T2/hu unknown
- 2012-04-04 JP JP2013546481A patent/JP5992924B2/ja active Active
- 2012-04-04 SG SG2013069273A patent/SG193468A1/en unknown
- 2012-04-04 PL PL12719460T patent/PL2694043T3/pl unknown
- 2012-04-04 SI SI201231192T patent/SI2694043T1/en unknown
- 2012-04-04 CA CA2832157A patent/CA2832157C/en active Active
- 2012-04-04 CN CN201810096214.1A patent/CN108042808B/zh active Active
- 2012-04-04 NZ NZ615591A patent/NZ615591A/en unknown
- 2012-04-04 PH PH1/2020/500280A patent/PH12020500280A1/en unknown
- 2012-04-04 CN CN201280017329.8A patent/CN103547260B/zh active Active
- 2012-04-04 DK DK12719460.3T patent/DK2694043T3/en active
- 2012-04-04 ES ES12719460.3T patent/ES2654851T3/es active Active
- 2012-04-04 MY MYPI2013701740A patent/MY166936A/en unknown
- 2012-04-04 EP EP17198877.7A patent/EP3299018A1/en not_active Withdrawn
- 2012-04-04 PH PH1/2020/552079A patent/PH12020552079A1/en unknown
-
2013
- 2013-09-17 ZA ZA2013/06981A patent/ZA201306981B/en unknown
- 2013-10-01 IL IL228669A patent/IL228669B/en active IP Right Grant
- 2013-11-05 CO CO13261085A patent/CO6801769A2/es not_active Application Discontinuation
-
2014
- 2014-05-09 HK HK18105601.0A patent/HK1246159A1/en unknown
-
2016
- 2016-08-18 JP JP2016160872A patent/JP2017031155A/ja active Pending
- 2016-12-21 US US15/386,289 patent/US20170100395A1/en not_active Abandoned
-
2017
- 2017-10-19 US US15/788,102 patent/US20180042923A1/en not_active Abandoned
-
2018
- 2018-01-17 CY CY20181100057T patent/CY1120567T1/el unknown
- 2018-07-20 US US16/041,246 patent/US20180325894A1/en not_active Abandoned
-
2021
- 2021-02-25 JO JOP/2021/0035A patent/JOP20210035A1/ar unknown
- 2021-03-10 US US17/197,725 patent/US20220000861A1/en not_active Abandoned
-
2023
- 2023-08-25 US US18/455,757 patent/US20240156811A1/en not_active Abandoned
-
2024
- 2024-10-07 US US18/907,757 patent/US20250177385A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019015237A (es) | Combinaciones que comprenden brexpiprazol o una sal del mismo y un segundo farmaco para el uso en el tratamiento de un trastorno del sistema nervioso central. | |
| CL2012001397A1 (es) | Compuestos hetero-triciclicos condensados, moduladores de quinasa jak; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la prepararcion de medicamentos utiles en el tratamiento de enfermedades autoinmunes, cancer y trastornos del sistema nervioso central, entre otras. | |
| CO6751271A2 (es) | Imidazol[5,1-f][1,2,4]triazinas para el tratamiento de trastornos neurológicos | |
| CO6501189A2 (es) | Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos | |
| MX2015012867A (es) | Compuestos aromaticos multisustituidos como inhibidores de serina proteasa. | |
| DOP2013000192A (es) | Compuestos y composiciones como inhibidores de la trk | |
| BR112013032178A2 (pt) | método de administração de 4-((1r,3s)-6-cloro-3-fenil-indan-1-il)-1,2,2-tri-metil-piperazina e os seus sais no tratamento de esquizofrenia | |
| EA201171493A1 (ru) | МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК | |
| DOP2014000008A (es) | 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk | |
| BR112015008759A2 (pt) | método para a profilaxia e/ou tratamento de sintomas comportamentais e psicológicos associados com doença neurodegenerativa ou sintomas impulsivos associados com doença mental, agente profilático e/ou terapêutico para sintomas comportamentais e psicológicos associados com doença neurodegenerativa ou sintomas impulsivos associados com doença mental, uso de um composto, composto, e, composição farmacêutica | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| GT201400053A (es) | Inhibidores de aplicación viral | |
| ECSP099620A (es) | Derivados de ciclohexano espirociclico | |
| CO6390058A2 (es) | Piperidina espiro pirrolidinona y piperidinona sustituidas usadas como moduladores de h3 | |
| CR20130056A (es) | Derivados heterocíclicos fusionados como moduladores s1p | |
| GT201300304A (es) | 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia | |
| CO6390059A2 (es) | Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, su preparación y su uso terapéutico | |
| DOP2016000251A (es) | Inhibidores de las vías de señalización de wnt | |
| ECSP15011105A (es) | siRNA Y SU USO EN LOS MÉTODOS Y COMPOSICIONES PARA EL TRATAMIENTO Y/O PREVENCIÓN DE TRASTORNOS OCULARES | |
| CO6771455A2 (es) | Composición de inhibidor vírico para uso terapéutico in vivo | |
| AR073711A1 (es) | Derivados de isoquinolina | |
| TH151403A (th) | ตัวยารวมซึ่งประกอบรวมด้วยเบรกซ์พิแพรโซลหรือเกลือของสารนั้น และยาชนิดที่สองสำหรับใช้ในการรักษาโรคของ cns | |
| CR10339A (es) | Derivados de sulfonil-3-heterociclilindazol como ligandos de 5-hidroxitriptamina-6 | |
| Fatima | Antidepressant triggering mania in bipolar disorder | |
| CU20100220A7 (es) | Heterociclos que contienen nitrógeno fusionado y composiciones de los mismos como inhibidores de cinasa |